An open label trial of anakinra to prevent respiratory failure in COVID-19

BACKGROUND: It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19. METHODS: A total of 130 patients with suPAR ≥6 ng/ml were assigned to subcutaneous anakinra 100 mg once daily for 10 days. Primary outcome was SRF incidence by day 14 defined...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyriazopoulou, Evdoxia, Panagopoulos, Periklis, Metallidis, Symeon, Dalekos, George N, Poulakou, Garyphallia, Gatselis, Nikolaos, Karakike, Eleni, Saridaki, Maria, Loli, Georgia, Stefos, Aggelos, Prasianaki, Danai, Georgiadou, Sarah, Tsachouridou, Olga, Petrakis, Vasileios, Tsiakos, Konstantinos, Kosmidou, Maria, Lygoura, Vassiliki, Dareioti, Maria, Milionis, Haralampos, Papanikolaou, Ilias C, Akinosoglou, Karolina, Myrodia, Dimitra-Melia, Gravvani, Areti, Stamou, Aliki, Gkavogianni, Theologia, Katrini, Konstantina, Marantos, Theodoros, Trontzas, Ioannis P, Syrigos, Konstantinos, Chatzis, Loukas, Chatzis, Stamatios, Vechlidis, Nikolaos, Avgoustou, Christina, Chalvatzis, Stamatios, Kyprianou, Miltiades, van der Meer, Jos WM, Eugen-Olsen, Jesper, Netea, Mihai G, Giamarellos-Bourboulis, Evangelos J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Immunology and Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034977/
https://www.ncbi.nlm.nih.gov/pubmed/33682678
http://dx.doi.org/10.7554/eLife.66125

Ejemplares similares

Ejemplares similares